Connecting Neuronal Cell Protective Pathways and Drug Combinations in a Huntington’s Disease Model through the Application of Quantitative Systems Pharmacology

被引:0
|
作者
Fen Pei
Hongchun Li
Mark J. Henderson
Steven A. Titus
Ajit Jadhav
Anton Simeonov
Murat Can Cobanoglu
Seyed H. Mousavi
Tongying Shun
Lee McDermott
Prema Iyer
Michael Fioravanti
Diane Carlisle
Robert M. Friedlander
Ivet Bahar
D. Lansing Taylor
Timothy R. Lezon
Andrew M. Stern
Mark E. Schurdak
机构
[1] Department of Computational and Systems Biology,
[2] University of Pittsburgh,undefined
[3] National Center for Advancing Translational Sciences,undefined
[4] National Institutes of Health,undefined
[5] Department of Neurological Surgery,undefined
[6] University of Pittsburgh,undefined
[7] University of Pittsburgh Drug Discovery Institute,undefined
[8] Department of Pharmaceutical Sciences,undefined
[9] University of Pittsburgh,undefined
[10] University of Pittsburgh Brain Institute,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Quantitative Systems Pharmacology (QSP) is a drug discovery approach that integrates computational and experimental methods in an iterative way to gain a comprehensive, unbiased understanding of disease processes to inform effective therapeutic strategies. We report the implementation of QSP to Huntington’s Disease, with the application of a chemogenomics platform to identify strategies to protect neuronal cells from mutant huntingtin induced death. Using the STHdhQ111 cell model, we investigated the protective effects of small molecule probes having diverse canonical modes-of-action to infer pathways of neuronal cell protection connected to drug mechanism. Several mechanistically diverse protective probes were identified, most of which showed less than 50% efficacy. Specific combinations of these probes were synergistic in enhancing efficacy. Computational analysis of these probes revealed a convergence of pathways indicating activation of PKA. Analysis of phospho-PKA levels showed lower cytoplasmic levels in STHdhQ111 cells compared to wild type STHdhQ7 cells, and these levels were increased by several of the protective compounds. Pharmacological inhibition of PKA activity reduced protection supporting the hypothesis that protection may be working, in part, through activation of the PKA network. The systems-level studies described here can be broadly applied to any discovery strategy involving small molecule modulation of disease phenotype.
引用
收藏
相关论文
共 50 条
  • [21] A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease
    Geerts, Hugo
    Walker, Mike
    Rose, Rachel
    Bergeler, Silke
    van Der Graaf, Piet H.
    Schuck, Edgar
    Koyama, Akihiko
    Yasuda, Sanae
    Hussein, Ziad
    Reyderman, Larisa
    Swanson, Chad
    Cabal, Antonio
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (04): : 444 - 461
  • [22] A neuro-dynamic quantitative systems pharmacology (QSP) model for Alzheimer's disease incorporating amyloid and Tau pathophysiology
    Cao, Y.
    Willis, B.
    van Rensburg, M.
    Davies, N.
    Sachdev, P.
    Penner, N.
    Wildsmith, K.
    Charil, A.
    Horie, K.
    Koyama, A.
    Reyderman, L.
    AUSTRALASIAN JOURNAL ON AGEING, 2024, 43 : 25 - 25
  • [23] Quantitative systems pharmacology model of thrombopoiesis and platelet life-cycle, and its application to thrombocytopenia based on chronic liver disease
    Shimizu, Ryosuke
    Katsube, Takayuki
    Wajima, Toshihiro
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (05): : 489 - 499
  • [24] SUPT4H1-edited stem cell therapy rescues neuronal dysfunction in a mouse model for Huntington’s disease
    Hyun Jung Park
    Areum Han
    Ji Yeon Kim
    Jiwoo Choi
    Hee Sook Bae
    Gyu-bon Cho
    Hyejung Shin
    Eun ji Shin
    Kang-in Lee
    Seokjoong Kim
    Jae Young Lee
    Jihwan Song
    npj Regenerative Medicine, 7
  • [25] Fibroblast Growth Factor 9 Stimulates Neuronal Length Through NF-kB Signaling in Striatal Cell Huntington’s Disease Models
    Issa Olakunle Yusuf
    Hsiu-Mei Chen
    Pei-Hsun Cheng
    Chih-Yi Chang
    Shaw-Jenq Tsai
    Jih-Ing Chuang
    Chia-Ching Wu
    Bu-Miin Huang
    H. Sunny Sun
    Chuan-Mu Chen
    Shang-Hsun Yang
    Molecular Neurobiology, 2021, 58 : 2396 - 2406
  • [26] Fibroblast Growth Factor 9 Stimulates Neuronal Length Through NF-kB Signaling in Striatal Cell Huntington's Disease Models
    Yusuf, Issa Olakunle
    Chen, Hsiu-Mei
    Cheng, Pei-Hsun
    Chang, Chih-Yi
    Tsai, Shaw-Jenq
    Chuang, Jih-Ing
    Wu, Chia-Ching
    Huang, Bu-Miin
    Sun, H. Sunny
    Chen, Chuan-Mu
    Yang, Shang-Hsun
    MOLECULAR NEUROBIOLOGY, 2021, 58 (05) : 2396 - 2406
  • [27] QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL OF ALZHEIMER'S DISEASE PREDICTS EFFECT OF TAU-DIRECTED IMMUNOTHERAPY ON MULTIPLE BIOMARKERS.
    Karelina, T.
    Demin, O.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S33 - S33
  • [28] QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL OF ALZHEIMER'S DISEASE PREDICTS EFFECT OF TAU-DIRECTED IMMUNOTHERAPY ON MULTIPLE BIOMARKERS.
    Karelina, T.
    Demin, O.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S114 - S114
  • [29] Quantitative systems pharmacology model of α-synuclein pathology in Parkinson's disease-like mouse for investigation of passive immunotherapy mechanisms
    Ivanova, Olga
    Karelina, Tatiana
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (10): : 1798 - 1809
  • [30] SYSTEMS PHARMACOLOGY IN NEUROSCIENCE: DEVELOPMENT AND APPLICATION OF A BETA-AMYLOID AGGREGATION MODEL TO PHARMACOLOGICAL TARGETS IN ALZHEIMER'S DISEASE
    Nicholas, T.
    Barton, H. A.
    Lu, Y.
    Duvvuri, S.
    Tatiana, K.
    Oleg, D.
    Kirill, Z.
    Sergey, B.
    Oleg, D., Jr.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S4 - S4